医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Catalent Announces Two Senior Appointments to Drive Growth in China

2013年04月16日 PM11:40
このエントリーをはてなブックマークに追加


 

SOMERSET, N.J.

Catalent Pharma Solutions today announced that it has made two senior appointments to support its recently established joint ventures in China for its Softgel Technologies and Clinical Supply Solutions (CSS) businesses. Dr. Weiyan “Jackson” Zhu has joined as Catalent’s Country General Manager for China, while Yufeng (Paul) Cao becomes the new Site Operations Director, for the 31,000 sq ft Catalent (Shanghai) Clinical Trial Supplies Co., Ltd facility, which is currently under construction. Dr. Zhu and Mr. Cao will both be based in Shanghai.

Dr. Zhu will play a pivotal role in Catalent’s China growth strategy, focusing on business development and government agency interaction. He will also liaise with Catalent’s local teams, which are currently being put in place, to assist with the startup of the company’s new operations.

He joins Catalent following a long tenure at Boehringer Ingelheim, where he had the distinction of being the company’s first, mainland China hire in its 120 year history. After joining Boehringer Ingelheim as a sales manager in 1998, Dr. Zhu held roles of increasing responsibility, including a position based in Germany as the regional business manager of Europe. Most recently, he served as Vice President and head of Boehringer Ingelheim consumer health care division in China.

Dr. Zhu received his Executive MBA from Shanghai Jiaotong University and a doctorate in philosophy from Zhejiang University.

In the second appointment, Mr. Cao will have overall day-to-day responsibility for Catalent and ShangPharm’s China Joint Venture business and will be in charge of establishing the new Shanghai clinical trial operation. He will lead Catalent’s local China CSS team to complete the site construction and launch operations by late summer 2013. Among his responsibilities, Mr. Cao will be in charge of developing the supply chain for the CSS operation and developing a customer service oriented team.

Prior to joining Catalent, Mr. Cao was most recently the General Manager for Fisher Clinical Service (Beijing, China). An industry veteran, who is experienced with GMP and FDA certification in China, he has an extensive background in secondary packaging and cold chain distribution. Prior to Fisher he worked for Zuellig Pharma and has extensive experience in drug distribution.

Mr. Cao has a Bachelor of Science Degree in Industrial Electrical Automation from Beijing University of Science and Technology and also holds an MBA from Vlerick Leuven Gent Management School, K. U. Leuven, Belgium. Additionally, he has a Bachelors degree in Computer Science & Artificial Intelligence from K. U. Leuven, Belgium.

Welcoming the new appointments, Catalent’s President & CEO, John Chiminski, commented, “We are pleased to have obtained the services of two such experienced and talented individuals as we expand into this new market. Jackson’s appointment is key to defining and executing an enterprise approach to driving our growth in China, initially through the joint ventures that we recently announced for Softgel Technologies and Clinical Supplies Services in Haining and Shanghai, respectively.” He continued, “For our CSS business in China, developing the client base locally, and catering to the trial and logistics needs from international clinical customers will be the most important aspect of Paul’s role. He will work closely with the Catalent CSS network sites and functional staff to drive CSS success in this important market.”

About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.

more products. better treatments. reliably supplied.™

CONTACT

Catalent Pharma Solutions
Chris Halling, +44 (0) 7580 041073
Chris.halling@catalent.com
or
NEPR
Richard
Kerns, +44 (0) 161 728 5880
richard@nepr.eu

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer